Affordable Access

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

Dove Press
Publication Date
  • Drug Design
  • Development And Therapy
  • Medicine
  • Pharmacology


Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the first once daily mesalamine product approved by the Food and Drug Administration for the maintenance of UC remission. This review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in UC maintenance.Keywords: ulcerative colitis, 5-ASA, mesalamine, adherence, compliance, quality of life, costs

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Maintaining remission in ulcerative colitis--role...

on Drug Design Development and Th... 2011

Maintaining remission in ulcerative colitis – role...

on Drug Design Development and Th... Jan 01, 2011

Inducing and maintaining remission in ulcerative c...

on Journal of clinical gastroente... September 2010

Once-daily MMX(®) mesalamine for endoscopic mainte...

on The American Journal of Gastro... July 2012
More articles like this..